Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mix...( PARIS September 10 /- - Abstra...),Health

PARIS, September 10 /PRNewswire-FirstCall/ --

- Abstracts 186 and 1003

Sanofi-aventis announced today that results from two studies, GINGER and LACE, presented at the 44th annual meeting of the European Association for the Study of Diabetes (EASD) demonstrated that a basal-bolus insulin regimen with LANTUS(R) (insulin glargine (rDNA origin) injection) once daily (basal insulin) and rapid-acting APIDRA(R) (insulin glulisine [rDNA origin] injection) at mealtime (bolus insulin) produced greater A1C reductions versus pre-mixed insulin in people with type 2 diabetes. Both studies, GINGER (a clinical trial) and LACE (real life patient data) confirmed the superior efficacy of LANTUS(R)/APIDRA(R) basal-bolus therapy when compared to pre-mixed insulin regimens.

Basal-bolus insulin regimens that combine once-daily LANTUS(R) as a basal insulin with rapid-acting APIDRA(R) at mealtime closely mimic normal physiologic insulin secretion that occurs in people without diabetes.

"Basal-bolus insulin regimens can be considered a gold standard for patients with late stage type 2 diabetes who have difficulty achieving glycemic targets with oral medications and/or basal insulin alone," explained study author Andreas Fritsche, MD, IVth Medical Department, University of Tübingen, Germany.

When compared to pre-mixed insulin regimens, the GINGER and LACE data demonstrate an efficacy advantage and, in the LACE study, a cost advantage for the basal-bolus approach.

The GINGER and the LACE data demonstrate an efficacy advantage and, in the LACE study, a cost advantage for the basal-bolus approach.

- The GINGER study ("52-Week, Open, Randomized, Multinational, Multicenter Clinical Trial Comparing Insulin Glulisine in Combination With Insulin Glargine in an Intensified Insulin Regimen to a Two-Injection Conventional Insulin Regimen in Type 2 Diabetes Mellitus Patients With Poor Glycemic Control Pretreated With a Two-Injection Conventional Pre
'/>"/>